Source : THE AGE NEWS
By James Pearson
ASX-listed Proteomics International Laboratories is gearing up for the global rollout of its revolutionary blood test for oesophageal cancer, PromarkerEso, by assembling a powerhouse clinical advisory board stacked with some of the world’s leading specialists in gastroenterology and cancer diagnostics.
The Perth-based precision diagnostics trailblazer has assembled the high-powered group to steer its commercialisation push, as the company readies to soon launch PromarkerEso in Australia and then beyond.
Proteomics International Laboratories ls launching its PromarkerEso oesophageal cancer test globally, backed by a top-tier clinical board of global gastrointestinal and cancer diagnostic experts.
PromarkerEso is a first-in-class blood test designed to detect a particularly prominent type of oesophageal cancer, oesophageal adenocarcinoma, often linked to chronic acid reflux, which affects one in five Americans.
Oesophageal adenocarcinoma diagnoses have surged six-fold globally in the past 40 years making the disease one of the leading causes of cancer deaths. The company says the grim statistics mean that achieving an accurate and non-invasive diagnostic test has become more urgent than ever.
The (advisory board’s) expertise and clinical insights will be invaluable as we introduce PromarkerEso to global markets.”
Proteomics International managing director Dr Richard Lipscombe
Trials of PromarkerEso have shown a 94 per cent accuracy rate in picking up the cancer using a cutting-edge combination of glycoprotein biomarkers, age and body mass index.
The test uses a traffic light-style risk score that ranges from green for low risk, amber for moderate risk and red for high risk. Patients at risk are flagged for further endoscopic testing.
Proteomics already has test patents in the bag across Europe, China and Australia. Having secured a dream team of seven key clinical leaders to sit on its new clinical advisory board, the company is moving closer to cracking open a massive global market, including in North America.
The global experts will help shape PromarkerEso’s clinical strategy and support its commercial rollout on the international stage.
The board includes leading UK surgeon Professor Hugh Barr, chief investigator of the landmark Barrett’s Oesophagus Surveillance Study, and his Barrett’s colleague Professor Krish Ragunath, a specialist in oesophageal management.
The group also includes the Dutch pioneer in oesophageal cancer imaging and biomarker development, Professor Jacques Bergman, and United States-based thoracic surgeon Professor Andrew Chang, Mayo Clinic AI researcher and gastroenterologist Professor Prasad Iyer, keyhole surgery specialist Dr Daniela Molena and pathologist Dr Robert Odze.
Proteomics International managing director Dr Richard Lipscombe said: “Their expertise and clinical insights will be invaluable as we introduce PromarkerEso to global markets and strive to make a meaningful impact on the lives of people living with chronic acid reflux.”
With market-ready technology, regulatory runs on the board and now a world-class advisory team in its corner, the company has firmly planted its flag as a frontrunner in early cancer detection and precision medicine – potentially saving lives in the process.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
